1月6日 - ** 药物开发商Arrowhead Pharmaceuticals ARWR.O股价大涨15.3%至73.66美元
** 该公司称，早期试验显示，其实验性疗法ARO-INHBE与礼来公司LLY.N的替唑帕肽联用后，2型糖尿病肥胖患者的体重在16周内平均减轻了9.4%。
** 在另一项早期试验中，co's 公司的另一种基于基因的肥胖症试验性疗法 ARO-ALK7 在 8 周内平均减少了 88% 的 ALK7 基因
** 通过改变脂肪细胞储存和燃烧能量的方式，靶向 ALK7 基因有助于治疗肥胖症和新陈代谢紊乱。
** 两种实验性疗法的耐受性都很好--ARWR
** ARWR 在过去 12 个月中增长了两倍多
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.